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Abstract: Arrhythmogenic cardiomyopathy (ACM) is primarily a familial disease with autosomal
dominant inheritance. Incomplete penetrance and variable expression are common, resulting in
diverse clinical manifestations. Although recent studies on genotype–phenotype relationships have
improved our understanding of the molecular mechanisms leading to the expression of the full-blown
disease, the underlying genetic substrate and the clinical course of asymptomatic or oligo-symptomatic
mutation carriers are still poorly understood. We aimed to analyze different phenotypic expression
profiles of ACM in the context of the same familial genetic mutation by studying nine adult cases from
four different families with four different familial variants (two plakophilin-2 and two desmoglein-2)
from the Swiss Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) Registry. The affected
individuals with the same genetic variants presented with highly variable phenotypes ranging from
no disease or a classical, right-sided disease, to ACM with biventricular presentation. Moreover,
some patients developed early-onset, electrically unstable disease whereas others with the same
genetic variants presented with late-onset electrically stable disease. Despite differences in age,
gender, underlying genotype, and other clinical characteristics, physical exercise has been observed
as the common denominator in provoking an arrhythmic phenotype in these families.
Keywords: arrhythmogenic cardiomyopathy; phenotype; genetics; exercise
1. Introduction
Arrhythmogenic cardiomyopathy (ACM) is a progressive, heritable cardiac condition with a
highly variable phenotypic manifestation [1]. The classic form of ACM is arrhythmogenic right
ventricular cardiomyopathy (ARVC), which is one of the leading causes of sudden cardiac death (SCD),
especially in the young, athletic population. In up to 11% of index cases, SCD is the first disease
expression, occurring even before manifestation of structural changes [2]. Approximately 60% of
ARVC patients carry a genetic mutation [3], with the majority of genes coding for components of the
desmosomes, which are essential for the structural integrity between cardiomyocytes [4], including
plakophilin-2 (PKP2), plakoglobin (JUP), desmoglein-2 (DSG2), desmocollin-2 (DSC2) and desmoplakin
(DSP). Inverted T waves and QRS prolongation in the right precordial leads (V1–V3) are among the
common surface electrocardiogram (ECG) abnormalities typically seen in ARVC, accompanied by
arrhythmias of right ventricular (RV) origin. Even though structural abnormalities are most dominant
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in the RV, left ventricular (LV) involvement may also occur with disease progression, and is rather
common [5]. For example, while pathogenic variants in PKP2 are usually associated with the classical
form of ARVC [6], LV involvement can be observed in later stages of the disease. On the other hand,
in the presence of DSG2 or DSC2 pathogenic variants, biventricular or LV-dominant phenotypes are
quite common even in early disease [7].
Even though studies on the genotype–phenotype relationship in ARVC improved our
understanding of the molecular mechanisms leading to the expression of the full-blown disease,
the underlying genetic substrate and the clinical course of asymptomatic or oligo-symptomatic
mutation carriers are still poorly understood. The aim of this case series was to analyze different
phenotypic expression profiles of ARVC in the context of the same familial genetic mutation.
2. Experimental Section
Clinical characteristics of nine adult cases diagnosed with ARVC from the Swiss ARVC Registry
belonging to four different families were analyzed. Demographic data, presenting complaints, physical
findings, and data from 12-lead ECG, transthoracic echocardiography (TTE), cardiac magnetic resonance
imaging (MRI), electrophysiological study (EP study), as well as treatment data were collected from
the medical records. The genetic analyses were performed through next generation sequencing
(NGS) in the probands using the TruSight cardio panel (Illumina), which contains 176 cardiac disease
genes. Our analysis focused on cardiomyopathy genes: ABCC9, ACTC1, ACTN2, ANKRD1, BAG3,
CAV3, CRYAB, CSRP3, DES, DMD, DSC2, DSG2, DSP, DTNA, EMD, FHL2, GLA, JUP, LAMA4,
LAMP2, LMNA, LDB3, MYBPC3, MYH6, MYH7, MYL2, MYL3, MYLK2, NEXN, PKP2, PLN, PRKAG2,
RBM20, SGCD, TAZ, TCAP, TGFB3, TMEM43, TMPO, TNNC1, TNNI3, TNNT2, TPM1, TTN, TTR,
VCL. In family members, genetic analyses were performed through polymerase chain reaction (PCR)
and Sanger Sequencing of single genes. The pathogenicity of genetic variants was assessed and
confirmed by a clinical cardiogeneticist (AMD), according to the 2015 American College of Medical
Genetics (ACMG) criteria [8], and modified by additional evidence from www.arvcdatabase.info and
VarSome [9]. The study was approved by the Zurich Cantonal Ethical Committee (KEK-ZH-NR:
2014-0443). All patients signed a written informed consent for participation in this study.
3. Results
Figure 1 shows the family tree of all four families. Table 1 shows which of the current ARVC Task
Force Criteria are fulfilled for each patient, while the imaging and ECG characteristics for all patients
are shown in Table 2.
Family 1: this family with three cases harbors a pathogenic (P, Class V) heterozygous variant in
PKP2 (c.2146 − 1G > C).
The proband, a 56-year-old man, had been referred to our department initially at the age of
26, after experiencing multiple episodes of syncope. He was diagnosed with ARVC following TTE,
RV angiography and EP study, during which a monomorphic ventricular tachycardia (VT) arising
from the RV could be induced. He was implanted with a single-chamber implantable cardioverter
defibrillator (ICD) at the age of 34. Based on the current 2010 Task Force Criteria, he has a diagnosis
of definite ARVC (Table 1). His last TTE showed a heavily dilated RV with reduced function and a
subtricuspid aneurysm, but no LV involvement. The patient underwent device replacements in 2003
and 2012, and is currently managed with amiodarone 100 mg once every other day and metoprolol
100 mg once daily. The patient used to be an endurance athlete (competitive soccer player) and still
exercises at a moderate level at present time, despite recommendations to further reduce physical
activity. The sister of the proband, a 65-year-old woman with the same genetic variants, who has never
engaged in physical activity, remains completely asymptomatic up to date.
The niece of the proband, with a history of autoimmune hepatitis, was referred to our department
in 2019 (at the age of 34) for evaluation of palpitations due to recurrent premature ventricular
contractions (PVC) and dyspnea (New York Heart Association Class II). Based on the 2010 Task Force
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Criteria she has a diagnosis of definite ARVC with LV involvement (Table 1). Her last TTE showed
a heavily dilated RV with reduced function and an apical aneurysm, and LV anteroseptal regional
wall abnormalities. MRI showed a significantly dilated RV, depressed RV function with regional
dyskinesia, microaneurysms, and late gadolinium enhancement (LGE) showing transmural fibrosis of
the anteroseptal portion of the LV. EP study showed an inducible VT with RV inferobasal origin during
isoprenalin provocation. Thus, a single-chamber ICD was implanted. The patient has been moderately
physically active and is currently managed with metoprolol 25 mg daily.
Figure 1. Family trees: Family 1: PKP2 c.2146 − 1G > C; * asymptomatic; ** early, unstable electrical
presentation; *** early, stable electrical, biventricular presentation. Family 2: PKP2 c.1378 + 1G > C;
* asymptomatic; ** early, unstable electrical presentation. Family 3: DSG2 c.523 + 2T > C; * late, stable
electrical presentation; ** early, unstable electrical presentation. Family 4: DSG2 c.294G > A; * late,
stable electrical presentation; ** early, unstable electrical presentation. Arrow: Index patient.
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Table 1. Swiss Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) Task Force Criteria.
Task Force Criteria
Structural Histological Repolarization Conduction Arrhythmias Familial
TFC Score
Major Minor Major Minor Major Minor Major Minor Major Minor Major Minor
Family 1
Proband X N/A N/A X X X * X 9
Niece X N/A N/A X X * X 7
Family 2
Proband X N/A N/A X X X 7
Mother N/A N/A X 2
Brother N/A N/A X 2
Family 3
Proband X N/A N/A X X X 7
Father X N/A N/A X X 5
Family 4
Proband X N/A N/A X X X 8
Brother X N/A N/A X X 5
X = Task force criterion fulfilled; N/A = no availability of investigation; * = based on 24h Holter premature ventricular contractions (PVC) count, no electrocardiogram (ECG) available for
determination of ventricular tachycardia (VT) origin; TFC score: major criterion (2 points), minor criterion (1 point).





















Proband 26 M Yes 2.9 * 2.6 * 26 * N/A N/A N/A III, aVR, V1-V4 * 2.5 *
Niece 34 F No 2.3 * 2.1 * 30 * 147 * 38 * Yes * II, III, aVF, V1-V6 * 1.5 *
Family 2
Proband 19 M Yes 2.1 * 2.1 * 24 * 176 * 40 * Yes * II, III, aVF, V1-V3 * 3 *
Mother 58 F No N/A N/A 45 71 60 No aVR, aVL 0
Brother 30 M No N/A N/A 52 93 60 No aVR, V1 0
Family 3
Proband 18 F Yes 1.8 * 1.87 * 44 97 57 No aVR, V1-V3 * 3 *
Father 52 M No 2 * 1.8 * 35 79 62 No aVR 13.8 *
Family 4
Proband 21 F Yes N/A N/A 26 * N/A N/A N/A II, III, aVF, V1-V6 * 4 *
Brother 53 M No N/A N/A 28 * 81 61 Yes * II, III, aVF, V5-V6 * N/A
N/A = no availability of investigation; PLAX = parasternal long axis; PSAX = parasternal short axis; FAC = fractional area change; RVEDVi = right ventricular end diastolic volume
(indexed); RVEF = right ventricular ejection fraction; LGE = late gadolinium enhancement; PVC = premature ventricular contractions measured by 24 h Holter; * = pathologic measurements
giving the fulfillment of a major or minor Task Force Criterion.
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Family 2: this family with two cases harbors a pathogenic (P, Class V) heterozygous variant in
PKP2 (c.1378 + 1G > C).
The proband, a 30-year-old man, was referred initially at the age of 19 after experiencing syncope
during physical activity. His ECG showed PVCs of RV subtricuspid origin. An EP study showed
inducibility of a monomorphic VT arising from the RV outflow tract (RVOT). Based on the 2010 Task
Force Criteria, he was diagnosed with definite ARVC (Table 1). His last TTE showed a dilated RV with
reduced function with a hypokinetic free wall and multiple subtricuspid aneurysms. MRI showed
a heavily dilated RV with reduced function, regional dyskinesias and microaneurysms, as well as
fibrosis of the RV free wall. The patient underwent implantation of a single-chamber ICD. He has
been managed with sotalol 80 mg bid and is currently free of any further arrhythmias. This patient
had always been strongly physically active performing endurance activities (competitive rowing) at
maximum effort until disease diagnosis was made.
The mother of the proband, a 64-year old woman, was initially referred at the age of 58 because
of the presence of the same pathogenic genetic variant of the proband on genetic cascade screening.
No abnormalities were detected on ECG, TTE, MRI, and 48 h Holter. This year, the patient was referred
again following detection of multiple non-sustained VT episodes on 24 h Holter. An EP study did
not reveal any inducible arrhythmias. Since then, she has been managed with metoprolol 25 mg bid,
and has not experienced any further arrhythmias. This patient had never been physically active.
The brother of the proband, a 35-year-old male, was referred initially at the age of 30 because of
the presence of the same pathogenic genetic variant on genetic cascade screening. Upon complete
cardiologic screening, no abnormalities were found. This patient had been moderately physically active.
Family 3: this family with two cases harbors a pathogenic (P, Class V) heterozygous variant in
DSG2 (c.523 + 2T > C).
The proband, a 26-year-old woman, was referred initially at the age of 18 because of the incidental
ECG finding of T wave inversions in V1–V3. Based on the 2010 Task Force Criteria, she was diagnosed
with definite ARVC (Table 1). Her last TTE showed a dilated RV with normal function and a subtricuspid
aneurysm. An EP study was performed in 2013, which showed inducibility of a VT of superior axis
with left bundle branch block (LBBB) morphology. Furthermore, RV angiography confirmed ARVC
with the presence of a slightly dilated RV and inferoapical and RVOT aneurysms. She underwent
implantation of a dual-chamber ICD and has been managed with metoprolol 25 mg bid since then.
The patient used to perform endurance sports (long distance running), but she stopped competitive
sports after ICD implantation, and has been moderately active since then.
The father of the proband, a 56-year-old man, was referred initially at the age of 52 for cascade
screening and the presence of symptomatic PVCs of RV origin. Based on the 2010 Task Force Criteria,
he was diagnosed with definite ARVC (Table 1). His last TTE showed a dilated RVOT with reduced
function and a subtricuspid aneurysm. This patient had been moderately physically active. He refused
implantation of an ICD and has since then been stable under therapy with nebivolol 2.5 mg daily.
Family 4: this family with two cases harbors a likely pathogenic (Class IV) heterozygous variant
in DSG2 (c.152G > C).
The proband, a 49-year-old woman, was referred initially at the age of 21 after experiencing
syncope due to sustained VT. After diagnosis for definite ARVC (Table 1), she underwent implantation
of a single-chamber ICD. Her last TTE showed a dilated RV with reduced function and multiple
subtricuspid aneurysms, but no LV involvement. Furthermore, she had multiple VTs with left bundle
branch block (LBBB) morphology and superior axis. At the age of 36, the patient refused ICD
replacement, and since then, has been arrhythmia-free under metoprolol 25 mg daily. The patient
used to be an endurance athlete (running and mountain biking), but has consistently diminished her
physical activity after ARVC diagnosis.
The brother with no past medical history presented to the emergency department at the age of
53 with recurrent syncope due to sustained VT with right bundle branch block (RBBB) morphology
and superior axis. TTE showed a normal, non-dilated LV with normal EF, a dilated right atrium and
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dilated RVOT (33 mm) with reduced RV function and a hypokinetic RV free wall. MRI showed regional
dyskinesia and microaneurysms, as well as pronounced fibrosis and fatty infiltration of the RV free
wall. The patient underwent implantation of a single-chamber ICD for secondary prevention, and since
then, has been under bisoprolol 2.5 mg bid. The patient has always been moderately physically active.
4. Discussion
ACM is primarily a familial disease with autosomal dominant inheritance. Incomplete penetrance
and variable expression are common, resulting in diverse clinical manifestations [10]. Furthermore,
the clinical significance of the underlying genotype is unclear and its value in determining a clinical
strategy has been controversial. The four different families described in our cohort demonstrate the
challenges in clinical management of patients and their families with this disease.
4.1. Classical ARVC vs. Biventricular ACM
PKP2 mutations account for a significant proportion of ACM cases, usually leading to ARVC,
the classical RV dominant phenotype of ACM [11]. The clinical presentation is characterized by
the presence of palpitations, exertional syncope, T wave inversions in the right precordial leads,
ventricular arrhythmias with a LBBB pattern, and RV structural abnormalities on imaging in a young
adult (20–40 years). ARVC is typically progressive, and after long-standing disease, end-stage RV as
well as LV involvement may occur, leading to biventricular failure. In the biventricular variant of
ACM, which is typically accompanied by a mutation in the desmosomal genes DSP or DSG2, there is
involvement of both ventricles from early on. The disease shows regional RV dysfunction occurs along
with apicolateral and baso-inferior fibrofatty infiltration in the LV, in the absence of reduced LV systolic
function [12].
ACM patients may exhibit different phenotypes despite the same underlying genotype, as was
the case in Family 1. The proband with PKP2 genetic variant had a clear, RV-dominant ACM and a
classical arrhythmic presentation, whereas his niece with the same genetic variant had a biventricular
disease, with anteroseptal LV fibrosis and heart failure presentation. The proband had been very
engaged in endurance sports, such as soccer and cycling, prior to his diagnosis. It is well known
that excessive physical activity significantly contributes to early arrhythmic expression of disease,
which explains the highly arrhythmic phenotype in this patient, whereas his affected sister who
was never engaged in physical activity remained completely asymptomatic [13,14]. On the other
hand, biventricular presentation of disease in the presence of a PKP2 mutation, which was the case
in the other affected family member of the proband, is rather unlikely [15]. In such cases, other
confounding conditions such as inflammation may alter the clinical course of disease by acting as a
precipitating factor. This particular patient suffered from autoimmune disease, which might have
adversely contributed to disease progression. There has been growing evidence about the role of
immune system in patients with ACM [16], but its potential role in our above-mentioned case may
only be speculative. (Figure 2)
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Figure 2. Genotype–phenotype determinants in subjects with a PKP2 variant. The two families with a
plakophilin-2 mutation present a broad phenotypic spectrum: from asymptomatic disease carrier to
biventricular disease. While the clearest factor causing an early, unstable, and classic ARVC seems to
be physical exercise, it interesting to note the autoimmune/inflammatory component in the presence of
biventricular disease.
4.2. Early Onset ACM vs. No Disease
It is known that ACM probands usually present with more severe disease than the family
members [17]. While this is clearly a disease with variable penetrance, it is still quite interesting to note
how the presence of the same, clearly pathogenic, PKP2 genetic variant in a family, can present with
phenotypes, which are at the opposite end of the spectrum. The youngest family member (proband)
in Family 2 who used to be an endurance athlete, as he was a rower on a competitive level, had an
early-onset typical arrhythmic ARVC presentation whereas the much less athletic older brother and
mother did not show any phenotypic manifestation of the disease even during long-term follow-up.
(Figure 2) Clinical studies have shown that endurance athletes with desmosomal mutations were
not only more likely to be at risk of life-threatening arrhythmias, but also more often developed the
full ACM phenotype [13,14]. The RV of individuals with desmosomal mutations are particularly
vulnerable to pathologic remodeling in response to exercise. Endurance exercise in these patients may
facilitate myocyte uncoupling leading to fibrosis and adipocytosis as well as dysfunction of electrical
coupling, which in turn facilitate the occurrence of arrhythmias [18]. This has been shown in a murine
model by Kirchoff et al., using a PKP2-deficient mouse model, where endurance exercise accelerated
the development of RV dysfunction and ventricular arrhythmias [19]. Furthermore, while variants
in PKP2 are relatively common in ACM patients, harboring one PKP2 variant may not, by itself, be
sufficient to provoke overt clinical disease. Concomitant causes such as environmental factors, which
can be physical exercise, or a “second hit” in the same gene (compound heterozygosity) or in a second
desmosome-encoding gene (digenic heterozygosity) have been shown to be required for development
of the overt clinical phenotype. For this reason, other genes that encode proteins that either directly or
indirectly contribute to the function and integrity of cellular junctions need to be screened [20].
4.3. Early and Unstable Electrical Phenotype vs. Late and Stable Phenotype
The patients in Families 3 and 4 were affected by two different heterozygous missense DSG2
variants and demonstrated peculiar clinical phenotypes: an early unstable and highly arrhythmogenic
electrical phenotype in the female probands (in their early twenties) and a late, stable, electrical
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phenotype in older male family members. In both families, physical exercise again seemed to play a
dominant role in disease expression. The two female probands both used to be endurance athletes up
until their diagnosis, and fortunately experienced electrical stabilization after significantly reducing
their physical activity. These observations are in line with recent literature, which have suggested that
detraining may reduce the arrhythmic burden in a cohort of athletes with ACM [21]. (Figure 3)
Figure 3. Genotype–phenotype determinants in subjects with a DSG2 variant. The two families with a
desmoglein-2 mutation present similarly: early, unstable involvement in the female, athletic proband
and late involvement, partly precipitated by a concurrent ischemic substrate in the male, moderately
active, family member.
There is recent evidence that sex hormones may have an impact on susceptibility to occurrence
of various arrhythmias. It has been shown that elite female athletes have significantly higher values
of testosterone, when compared to controls [22]. Our group has recently shown that circulating sex
hormone levels, particularly high levels of testosterone and low levels of estrogen, may lead to adverse
arrhythmic outcomes in ARVC. This observation has also been confirmed in the experimental setting by
using a stem-cell derived cardiomyocyte-based model [23]. The novel finding of increased ventricular
arrhythmia susceptibility in patients with higher circulating levels of testosterone has also been verified
in another and genetically distinct ARVC patient cohort [24].
In summary, in all four families described above, endurance sport was the most important uniting
factor for phenotypic disease expression, independent of the underlying mutation. This is in line with
previous observations, which showed that the amount and intensity of exercise increases the likelihood
of adverse clinical outcomes in desmosomal mutation carriers [14].
5. Conclusions
Arrhythmogenic cardiomyopathy (ACM) is primarily a familial disease with autosomal dominant
inheritance. Incomplete penetrance and variable expression are common, resulting in diverse clinical
manifestations. Although recent studies on genotype–phenotype relationships have improved our
understanding of the molecular mechanisms leading to the expression of the full-blown disease,
the underlying genetic substrate and the clinical course of asymptomatic or oligo-symptomatic
mutation carriers are still poorly understood. Despite differences in age, gender, underlying genotype,
and other clinical characteristics, physical exercise has been observed as the common denominator in
provoking an arrhythmic phenotype in ACM.
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